Seidman AD - Search Results

1

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Seidman AD, et al. J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8. J Urol. 1992. PMID: 1371564 Clinical Trial.

2

The evolving role of chemotherapy for muscle infiltrating bladder cancer.

Seidman AD, Scher HI. Seidman AD, et al. Semin Oncol. 1991 Dec;18(6):585-95. Semin Oncol. 1991. PMID: 1775975 Review.

3

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

4

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

Seidman AD, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, et al. Seidman AD, et al. J Natl Cancer Inst Monogr. 1993;(15):171-5. J Natl Cancer Inst Monogr. 1993. PMID: 7517153

5

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.

Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Hudis CA, Surbone A, et al. Seidman AD, et al. Oncology. 1994 Oct;51 Suppl 1:33-9. doi: 10.1159/000227414. Oncology. 1994. PMID: 7526308 Clinical Trial.

6

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.

Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, et al. Seidman AD, et al. J Clin Oncol. 1995 May;13(5):1152-9. doi: 10.1200/JCO.1995.13.5.1152. J Clin Oncol. 1995. PMID: 7537798 Clinical Trial.

7

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.

Seidman AD, Scher HI, Gabrilove JL, Bajorin DF, Motzer RJ, O'Dell M, Curley T, Dershaw DD, Quinlivan S, Tao Y, et al. Seidman AD, et al. J Clin Oncol. 1993 Mar;11(3):408-14. doi: 10.1200/JCO.1993.11.3.408. J Clin Oncol. 1993. PMID: 7680373 Clinical Trial.

8

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.

Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, et al. Seidman AD, et al. Semin Oncol. 1993 Aug;20(4 Suppl 3):40-5. Semin Oncol. 1993. PMID: 7688145 Clinical Trial.

9

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

Schultz PK, Herr HW, Zhang ZF, Bajorin DF, Seidman A, Sarkis A, Fair WR, Scherr D, Bosl GJ, Scher HI. Schultz PK, et al. J Clin Oncol. 1994 Jul;12(7):1394-401. doi: 10.1200/JCO.1994.12.7.1394. J Clin Oncol. 1994. PMID: 8021730

10

Immune-mediated thrombocytopenia secondary to suramin.

Seidman AD, Schwartz M, Reich L, Scher HI. Seidman AD, et al. Cancer. 1993 Feb 1;71(3):851-4. doi: 10.1002/1097-0142(19930201)71:3<851::aid-cncr2820710331>3.0.co;2-m. Cancer. 1993. PMID: 8431868

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters